News

pharmaphorum1d
The mesenchymal stem cell’s superpower: Hacking the TME
What if we could reprogramme the TME itself? Cutting-edge research suggests that engineered mesenchymal stem cells (MSCs) ...
The Manila Times1d
Ernexa Therapeutics Establishes Texas Subsidiary to Support Continued Development of ERNA-101 and Future Clinical Operations
ERNA-101 remains on track for IND-enabling studies in 2025, with first-in-human studies targeted for 2026.
The Manila Times1d
INmune Bio Inc. Announces Attendance at the 2025 RBC Capital Markets Global Healthcare Conference
About INmune Bio Inc. INmune Bio Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease.
Protein DNM1 identified as key regulator in ovarian cancer metastasis
Ovarian cancer remains the leading cause of death among cancers affecting the female reproductive system, largely because ...
A new era in cancer therapies is at hand
The cells targeted the cancer and eradicated it. Thirteen years later, Whitehead is still cancer-free. Since then, however, ...
FMIBlog3d
Navigating the Cirrhosis Management Market: Trends, Treatment Innovations, and Future Outlook | FMI
Managed cirrhosis encompasses a wide range of medical interventions and therapeutic strategies aimed at halting disease progression, reducing complications, and enhancing the quality of life of ...
BioWorld5d
Cynata’s MSC cells show positive results across variety of delivery systems
The promise of mesenchymal stem cells (MSCs) to heal heart disease could be around the corner thanks to a new delivery method tested by regenerative medicine company Cynata Therapeutics Ltd.